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Das Krebs-assoziierte Stroma (CAS) beeinflusst die Entwicklung von 
Mammakarzinomen (mCA) in hohem Masse. Canine einfache mCA sind relevante 
Modelle für humane mCA, auch in Hinsicht auf CAS. Während Veränderungen des 
CAS-Transkriptoms in mCA gut beschrieben sind, ist unklar, inwieweit sich dessen 
Proteom verändert. Das Ziel dieser Arbeit war es, zu untersuchen, wie sich das 
Proteom im CAS caniner mCA von normalem Stroma unterscheidet, und inwiefern 
dies mit dem Transkriptom korreliert. Dafür analysierten wir CAS und normales 
Stroma mittels Laser-Mikrodissektion (LCM) und LC-MS/MS in einer Kohorte von 14 
formalin-fixierten, Paraffin-eingebetteten (FFPE) caninen mCA, die zuvor mittels 
LCM-RNAseq charakterisiert worden waren. Die Resultate zeigten deutliche 
Unterschiede der Proteinzusammensetzung zwischen normalem Stroma und CAS, 
welche vor allem durch Veränderungen in der extrazellulären Matrix, dem Zytoskelett 
und Zytokinen gekennzeichnet waren. Proteomik und RNAseq zeigten ein 
erhebliches Mass an Korrelation, insbesondere für stark deregulierte Zielstrukturen 
und aktivierte Signalwege. Schliesslich validierten wir die Hochregulierung von 
LTBP2, IGFBP2, COL6A5, POSTN, FN1, COL4A1, COL12A1, PLOD2, COL4A2 und 
IGFBP7 in CAS auf Proteinebene und zeigten ihren negativen prognostischen Wert 
für humanen Brustkrebs auf. In Anbetracht der Relevanz des caninen mCA als 
Modell für die menschliche Erkrankung haben diese Resultate Implikationen für 
Brustkrebs beider Spezies. 
 
Schlüsselwörter: Tumor-Mikroumgebung, vergleichende Onkologie, Brustkrebs, 
Tumorstroma, canine Mammakarzinome  
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 Summary 
Cancer-associated stroma (CAS) profoundly influences progression of tumors 
including mammary carcinoma (mCA). Canine simple mCA represent relevant 
models of human mCA, notably also with respect to CAS. While transcriptomic 
changes in CAS of mCA are well described, the extent to which its proteome 
changes remains unclear. Therefore, we sought to gain insight into the proteomic 
changes in CAS and compare them with transcriptomic changes in the same tissue. 
To this end, we analysed CAS and matched normal stroma using laser-capture 
microdissection (LCM) and LC-MS/MS in a cohort of 14 formalin-fixed paraffin 
embedded (FFPE) canine mCAs that we had previously characterized using LCM-
RNAseq. Results revealed clear differences in protein composition between CAS and 
normal stroma, which were characterized by changes in the extracellular matrix, the 
cytoskeleton, and cytokines. Proteomics and RNAseq showed a substantial degree 
of correlation, especially for highly deregulated targets and activated signaling 
pathways. Finally, we validate upregulation of LTBP2, IGFBP2, COL6A5, POSTN, 
FN1, COL4A1, COL12A1, PLOD2, COL4A2, and IGFBP7 in CAS on the protein level 
and demonstrate their adverse prognostic value for human breast cancer. Given the 
relevance of canine mCA as a model for the human disease, these results have 
implications for breast cancer of both species. 
 
Keywords: Tumor microenvironment, comparative oncology, breast cancer, tumor 




bFGF   basic fibroblast growth factor 
CAF  cancer-associated fibroblasts 
CAS  cancer-associated stroma 
COL  collagen 
ECM  extracellular matrix 
ER  estrogen receptor 
FAP  fibroblast activation protein 
FISH  fluorescence in situ hybridization 
FC  fold change 
FDR  false discovery rate 
FFPE  formalin-fixated, paraffin-embedded  
HER2  human epidermal growth factor receptor 
LCM   laser-capture microdissection 
mAb  monoclonal antibody 
mCA  mammary carcinoma 
MMP  metalloproteinases  
PCA  principle component analysis 
PDGFRB  platelet-derived growth factor receptor beta 
RNAseq RNA sequencing 
TAMs  tumor-associated macrophages  
TGFβ  transforming growth factor beta 
TILs  tumor infiltrating lymphocytes 
TNF  tumor necrosis factor 




4.1. Breast cancer is a worldwide major health concern  
Cancer is a term used to describe a variety of diseases that occur when the organism 
loses control over mitotic propagation of single cells (LYNCH, 1987). This results in 
uncontrolled division of cells that can affect the whole body and leads to the 
formation of so-called tumors. Depending on their behavior with respect to healthy 
tissue, such tumors can be malignant or benign. While benign tumors remain in their 
original location, malignant tumors grow quickly, can invade the surrounding tissue 
and thereby spread to other parts of the body, also known as metastasis. Over 100 
different types of cancer are known to affect humans. Despite intense research 
efforts to promote knowledge of cancer biology and therapy, the number of deaths 
that are attributed to cancer has constantly risen over the past decades and currently 
presents the second leading cause of death worldwide (World Health Organization, 
2020). In 2020, 19.3 million new cases and 10 million death due to cancer were 
reported (Sung et al., 2021). Of all new cancer cases, 2.261.419 cases (11.7%) and 
684.996 of all deaths are due to breast cancer (6.9%). Indeed, breast cancer is the 
most commonly diagnosed cancer in women both worldwide and in Switzerland. 
Over a lifetime, 40% of the Swiss population gets diagnosed with cancer and 3 out of 
10 people will die because of it (Heusser et al., 2017). In 2020, Switzerland counted 
60.483 new cases of cancer of which 12% were breast cancer (International Agency 
for Research on Cancer, 2021). While the incidence of breast cancer has slowly risen 
over the past decades in Switzerland, the death rate has declined by 30% thanks to 
early diagnosis and improved therapy (Heusser et al., 2017). Yet, 2020 had a 
negative impact on cancer rates and outcomes as COVID-19 led to elevated 
mortality rates, delayed diagnosis, altered treatment pathways to reduce the risk of 
exposure to the virus, reduced available therapy options due to suspension of clinical 
trials (Liang et al., 2020; Richards et al., 2020). Accordingly, by systematically 
reviewing seven major cancer types and three treatment modalities, Hanna et al. 
corroborate the hypothesis that a delay in cancer treatment leads to a significant 
increased mortality rate (Hanna et al., 2020). Moreover, cancer research that relies 
on cancer patient samples was limited due to the lack of availability, thereby 
providing negative impact on progress in cancer treatment (Mulholland, 2021). Thus, 
cancer in general and breast cancer in particular remains a major worldwide health 
concern that requires continued efforts to further our understanding of the disease to 
improve its therapy and further increase patient survival. 
 
4.2. The importance of cancer-associated stroma in cancer biology 
The molecular basis of cancer is rooted in transformation of healthy cells towards 
cancer cells through genetic and/or epigenetic changes. Accordingly, the majority of 
cancer research has focused on understanding the behavior of these cancer cells, 
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which often derive from an epithelial origin. However, more recent progress has 
revealed that, much like a flower seed cannot grow without the appropriate soil, 
cancer cells cannot survive on their own and need appropriate stromal surroundings 
to sustain their survival and growth. This so-called “seed-and-soil” theory was already 
proposed back in 1889 by Stephen Paget, an English surgeon (Paget, 1889), but its 
molecular underpinnings have only begun to be investigated in detail over the last 
two decades. Through this progress it has become abundantly clear that the 
microenvironment that surrounds cancer cells, the so-called cancer-associated 
stroma (CAS), has profound effects on the development and survival of tumor cells, 
and thereby strongly influences clinical aspects of the disease (Gandellini et al., 
2012; Hanahan & Coussens, 2012; Song et al., 2019). Indeed, CAS has been shown 
to profoundly influence most of the hallmarks of cancer in a wide variety of tumors, 
including breast cancer (Hanahan & Coussens, 2012). CAS is composed of a large 
variety of normal, non-malignant cells including fibroblasts, immune cells, vascular 
cells, adipocytes, and others that reside in an insoluble extracellular matrix (ECM) 
composed of collagens and other structural elements. Under physiological 
circumstances, healthy stroma serves as an important barrier to prevent epithelial 
transformation. However, in the vicinity of malignant tumor cells, stroma is 
reprogrammed into CAS. This reprogramming of normal stroma to CAS is strongly 
driven by the adjacent cancer cells that produce a range of cytokines, growth factors 
and proteases which modify the surrounding stromal environment to their own 
advantage (Gkretsi et al., 2015; YUAN et al., 2016). In the following, I will shortly 
touch upon individual components of the CAS and their role on tumor biology. 
 
Cancer-associated fibroblasts 
As the main ECM-producing cells, fibroblasts are among the most abundant cells in 
the stroma. When normal fibroblasts are in close vicinity of cancer cells, this leads to 
their activation into so-called cancer-associated fibroblasts, or CAFs. CAFs are 
fibroblasts that differ phenotypically and functionally from their normal counterparts 
and strongly resemble myofibroblasts, which occur during physiological wound 
healing (Micallef et al., 2012; Östman & Augsten, 2009). In normal tissue, fibroblasts 
are key components of wound healing and inflammation and are known to be able to 
protect against malignant progression of epithelial cells (Coussens & Werb, 2016). 
During wound healing, fibroblast undergo transformation into myofibroblasts, which 
have an increased contractility that is important to mediate closure of the wound. 
Similarly, CAFs strongly resemble myofibroblasts in many aspects including 
increased contractility and it has been suggested that they can originate from various 
cell types. Through various cytokines and signaling molecules, neoplastic cells are 
able to activate fibroblasts into CAFs, which in turn strongly promote tumor 
progression (Bhowmick et al., 2004; Kalluri, 2016; Marsh et al., 2013; Sahai et al., 
2020; Tripathi et al., 2012). CAFs influence the tumor microenvironment by secreting 
and/or activating cytokines, growth factors, nutrients and proteases, all of which 
leads to tumor growth, expansion and dissemination of the pre-neoplastic epithelial 
cell population (Bissell & Radisky, 2001; Franco et al., 2010; Hanahan & Coussens, 
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2012). The influence of CAFs is evident also from the fact that the presence of 
specific subsets of CAFs have been shown to correlate with poor survival and 




Another important component of the CAS is formed by infiltrating immune cells. In a 
physiologically regulated environment, inflammation is a self-limiting process, 
meaning that pro-inflammatory cytokines are followed by anti-inflammatory cytokines 
to keep the inflammatory reaction under control. Any dysregulations of this process 
can lead to abnormalities, and ultimately, pathogenesis. Normally, the immune 
system recognizes transformed epithelial cells and removes these and thereby 
provides a very important defense mechanism to protect the organism from tumor 
development. Accordingly, an inflammatory component is present in the 
microenvironment of most neoplastic tissues, as the immune system recognizes 
illegitimate cell proliferation. However, cancer cells often learn how to avoid, blunt or 
redirect the immune attack, and sometimes even manage to use this continuous 
inflammation in their favor. For example, cancer cells can use the immune cells as a 
source of tumor-supportive cytokines (Colotta et al., 2009; Mantovani et al., 2008). 
Some of those cytokines can for instance activate transcription factors, such as NF-
kB, STAT3, and AP-1 which in turn induce expression of genes that stimulate cell 
proliferation and survival (Grivennikov et al., 2010).  
One main group of immune cells found in tumors are lymphocytes, which include T-
cells, B-cells, and natural killer (NK) cells. Lymphocytes that leave the blood stream 
and infiltrate the tumor are called tumor infiltrating lymphocytes (TILs). They can be 
found between tumor cells or in the CAS in most types of solid tumors (Badalamenti 
et al., 2019). As they have the capability to kill cancer cells, high amounts of TILs are 
usually correlated with a good prognosis (Bremnes et al., 2016; Mahmoud et al., 
2011; Toor et al., 2019; Wouters & Nelson, 2018). Accordingly, Verma et al. 
demonstrated that stromally located TILs that are positive for CD20 (B cells) or CD4 
(T cells) in ER negative breast cancer cases correlate with improved outcomes 
(Verma et al., 2020). Ali et al. revealed an impact of cytotoxic (CD8+) lymphocytes in 
ER-negative (both HER2-positive and HER2-negative) and ER-positive/HER2-
positive breast cancer on the survival rate (Ali et al., 2014). Women with presence of 
CD8+ cells show a higher survival rate than women without. In addition, the location 
of T cells, whether they are found in tumoral or stromal tissue, does not impact on the 
result (Ali et al., 2014). Furthermore, TILs can be used for immunotherapy by 
separation, amplification, and blood-transfusion. These TILs are isolated from tumor 
tissue of patients, so they are not genetically modified. Only the lymphocytes that 
show a specific killing effect on tumor will be amplified and later used in blood 
transfusions after the patient has received chemotherapy with the aim of targeting 
cancer cells that were not eradicated by it (Lin et al., 2020).  
Other important tumor-infiltrating cell types are macrophages that are derived from 
monocytes. By producing various angiogenic and lymphangiogenic growth factors, 
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different proteases and cytokines, macrophages play an important role in chronic 
inflammatory processes. They can be divided in two main groups, the classically 
activated “M1 macrophages” and the alternatively activated “M2 macrophages”. In 
contrast to M2 macrophages, M1 macrophages react in a pro-inflammatory way, 
whereas M2 are involved in anti-inflammatory responses and are associated with a 
worse clinical presentation (Larionova et al., 2020; Pan et al., 2020; Steidl et al., 
2010). Cancer cells can influence macrophages to turn into tumor associated 
macrophages (TAMs) that suppress antitumor immunity (Murray & Wynn, 2011). The 
number of TAMS and intratumoral lymphatics can also be used as prognostic 
markers for different types of cancer, for example colorectal cancer, where high 
numbers correlate with poor survival (Helm et al., 2014). A meta-analysis of sixteen 
studies related to breast cancer revealed that a high number of TAMs correlate with 
malignant biological behavior and poor overall survival (Zhao et al., 2017). Another 




For growth and progression, tumors require a functioning vasculature that provides a 
constant supply of oxygen and nutrients and enables removal of metabolic waste 
products. To cater to this demand, tumors induce formation new blood and lymph 
vessels. Indeed, it has been estimated that, without appropriate blood supply, tumors 
are not able to become lager than 1–2 mm3, mostly because simple diffusion of 
nutrients is not efficient enough to sustain the increased demands (Nishida et al., 
2006). To induce angiogenesis, tumors express a series of angiogenic factors, 
including vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF), angiogenic transforming growth factor (TGF)-alpha, TGF-beta, tumor 
necrosis factor (TNF), granulocyte colony-stimulation factor, placental growth factor, 




All previously discussed cells are embedded in the ECM, which is a three-
dimensional, non-cellular structure that provides a physical scaffold to ensure proper 
tissue architecture. Its components are proteoglycans, hyaluronic acid, and fibrous 
proteins (Egeblad et al., 2010). ECM is present in all tissues and is essential for life. 
We can differentiate between two main types of ECM, the interstitial connective 
tissue matrix and the basement membrane. The connective tissue matrix surrounds 
cells and provides a scaffold for the tissue, whereas the basement membrane can be 
found as a lining between the epithelium and surrounding stroma. The ECM 
contributes to paracrine cellular signaling and regulates many cellular processes 
including growth, migration, differentiation, survival, homeostasis, and 
morphogenesis (Frantz et al., 2010; Hynes & Naba, 2012; Theocharis et al., 2016). 
To be able to influence those processes, the ECM interacts with epithelial cells via for 
example ligands such as integrins or it releases growth factors, such as epidermal 
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growth factor (EGF), bFGF and others (Miyamoto et al., 1996; Williams et al., 1994). 
These also allow bidirectional communication between cells and ECM 
macromolecules. Moreover, The ECM is subject to a constant turnover and change 
through enzymes such as collagenases and matrix metalloproteinases (MMPS) that 
adapt the ECM according to structural needs of the tissue (Bonnans et al., 2014). 
Similarly, during cancer progression, strong changes in the abundance of different 
types of collagens can be observed in the ECM. Some of these collagen remodeling 
biomarkers can even be used to measure tumor activity in regard of progression and 
metastasis (Kehlet et al., 2016). 
 
In summary, a lot of knowledge regarding the role of CAS in tumor biology has been 
gained over the last two decades. A picture starts to emerge in which bidirectional 
interaction of tumor cells with the surrounding CAS is an absolute prerequisite for 
cancer to develop. Similarly, increased understanding of this dialogue has led to the 
development of several very promising therapeutic approaches, including 
immunotherapies. However, our understanding regarding CAS reprogramming and 
the molecular dialogue between CAS and cancer cells remains incomplete, 
especially so in actual patient samples. More detailed insight into the crosstalk of 
malignant cells with their surroundings has the potential to unravel novel therapeutic 
approaches to help treat patients suffering from cancer.  
 
 
4.3. Canine mammary tumors as a model for human breast cancer 
Cancer can affect a big variety of cells and is therefore used as an umbrella term for 
a large group of diseases. Even the same type of cancer can vary in for example 
behavior, symptoms, and location between individuals. This is exactly where 
“comparative oncology” might provide an advantage over historically used classical 
rodent tumor models. The basic concept of “comparative oncology” is to integrate the 
study of naturally occurring cancers in animals with that of human cancer and 
thereby facilitate identification of central pathways that are responsible for the 
disease. While it might seem quite unusual to use the dog as a model organism for 
humans at first sight, tumors in dogs share a lot of similarities with human cancer, 
and also present several advantages over widely used rodent models for cancer 
research. For instance, the environment that organisms are exposed to is a very 
important factor that strongly influences cancer development. Dogs often share the 
same environment as humans and therefore are exposed to much of the same risk 
factors. A lot of research is done in rodents or other laboratory animals which 
develop cancer under different conditions compared to humans. For example, tumor 
progression is extremely fast in mice compared to humans which limits the 
opportunities to study novel therapeutics. Instead, pets like dogs and cats are found 
to share more similarities especially in tumor development and progression (Hansen 
& Khanna, 2004; Vail & Macewen, 2000). In general, physiology of humans is more 
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comparable to dogs than to rodents regarding anatomy, size, physiology, 
metabolism, immunology, and genetics. And dogs and humans often show similar 
clinics and pathophysiology when it comes to cancer (Munson & Moresco, 2007). 
Furthermore, sequencing of the dog genome has demonstrated the presence of 
more consensus between the genome of human and dogs than between humans 
and mice (Hoffman & Birney, 2006; Lindblad-Toh et al., 2005).  
 
Based on clinical, histological, and molecular similarities, canine simple mammary 
carcinomas (mCA) are considered an excellent model for human breast cancer, also 
because they overcome several of the limitations of xenograft or genetically modified 
rodent tumor models (Liu et al., 2014; Queiroga et al., 2011; Schiffman & Breen, 
2015). Indeed, canine simple mCA not only emulate the biology of human mCA but 
also feature many of the genomic aberrations found therein (Liu et al., 2014; 
Queiroga et al., 2011b). mCA are the most frequent tumors in both women and intact 
female dogs (Salas et al., 2015). In contrast, female dogs that get neutered before 
their first estrus cycle, show an incidence for mCA of 0.05% compared to intact 
female dogs, which is thought to reflect the hormonal influence during tumor 
development (Rivera et al., 2009; Zatloukal et al., 2005). Similarly, women with a 
BRCA1 germline mutation can reduce their breast cancer risk by undergoing a 
prophylactic bilateral oophorectomy before menopause (Rebbeck et al., 1999). 
Canine simple mCA are malignant epithelial neoplasms that infiltrate the surrounding 
tissue, whereby they induce a strong stromal response, and can also give rise to 
metastases (Goldschmidt et al., 2011). Importantly, the similarities between human 
and canine mCA are not only limited to the tumor cells, but also extend to 
reprogramming of CAS. By analyzing CAS and normal stroma from formalin-fixed 
paraffin embedded (FFPE) breast cancer tissue using laser-capture-microdissection 
(LCM) through RNA sequencing (RNAseq) and quantitative PCR (RT-qPCR), our 
group has recently demonstrated the existence of strong molecular homologies in 
stromal reprogramming between human and canine mCA (Amini et al., 2017, 2019, 
2020; Markkanen, 2019). Hence, comparative study of CAS between human and 
canine mCA has the potential to reveal interesting new findings with regards to 
tumor-stroma crosstalk.  
While transcriptomic changes in CAS of both human and canine mCA are beginning 
to be understood, it remains unclear to what extent these differences in mRNA 
abundance actually translates to the protein level. Thus far, analytic approaches of 
CAS reprogramming in both human and canine patient samples of mCA have been 
mostly focused on analysis of RNA, therefore reflecting the transcriptional state of the 
tissue (Amini et al., 2019, 2020; Finak et al., 2008; Pepin et al., 2012). However, 
because RNA levels and protein abundance do not necessarily correlate 
(Greenbaum et al., 2003; Maier et al., 2009; Popovic et al., 2018), it remains entirely 
unclear to what extent the observed transcriptional changes translate to the protein 
level in both human and canine mCA. To the best of our knowledge, there is only one 
report describing proteomic changes in CAS in fresh-frozen samples of human mCA 
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(Braakman et al., 2017), and none for canine mCA. This striking shortage of data on 
a highly relevant aspect of tumor biology warrants further investigation.  
 
 
4.4. The power of prognostic markers 
For a cancer patient, the diagnosis is only the first step in a long journey towards 
recovery. After that, tumor stage and grade must be evaluated to be able to establish 
an individual therapy and predict survival chances. With new technologies and 
advances in the field of genomics, the interest in tumor makers that either predict 
patient’s overall outcome, called prognostic marker, or predictive markers, which 
indicates sensitivity or resistance to a specific type of therapy, have risen strongly 
over the last decades. Markers can also show both qualities, prognostic and 
predictive. They are used to detect if certain molecular structures such as proteins 
are up- or downregulated that are related to survival and prognosis. The ability to 
discover prognostic markers has increased with easier and more affordable DNA 
sequencing over the past 4 decades (Shendure et al., 2017). However, it remains a 
difficult task to find a prognostic marker that is specific for a malignant tumor, able to 
accurately predict the outcome of most patients, and easy to detect. Finding such 
markers involves multiple disciplines that need to work closely together in prognostic 
research. Two very common and widely used markers since decades are tumor size 
and histological grade (Carter et al., 1989; Donegan, 1997). For breast cancer, lymph 
node status and hormone receptor status are additional important prognostic factors. 
The hormone receptor status is routinely assessed, and tumors are categorized in 
‘hormone-receptor-positive’, ‘hormone-receptor negative’, ‘triple-negative’ and ‘triple-
positive’. Tumors that are positive for one or more hormonal receptors can be treated 
easier than those tumors that do not express either receptor or growth factor. Tumors 
are tested for the estrogen (ER)- and progesterone (PR)-receptors as well as the 
human epidermal growth-factor (HER) status. Dunnwald et al. analyzed data of 
155.175 women with breast cancer to evaluate a correlation between hormone 
receptor status and mortality. Women with ER+/PR+ had a lower risk of mortality 
compared to women with ER-/PR+, ER+/PR- or Er-/PR- (Dunnwald et al., 2007). 
Furthermore, Slamon et al. evaluated the efficacy of a monoclonal antibody against 
HER2 in combination with chemotherapy which prolongs survival in patients with 
metastatic breast cancer compared to patients that only received chemotherapy 
(Slamon et al., 2001). This emphasizes the prognostic power of the hormone 
receptor status. The downside of the listed factors is that they are not suitable 
markers for early diagnosed breast cancer patients (M. J. Duffy et al., 2016, 2017). 
Molecular prognostic markers can be downregulated, as for example the JAK1 
mRNA levels in breast cancer, which also correlates with poor survival (B. Chen et 
al., 2019). JAK1 is essential for certain cytokines and important for transducing 
interferon signals. Markers can also be upregulated, like Ki67, which is widely used 
to measure and monitor proliferation of mammary tumors (Shoker et al., 2001; 
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Urruticoechea et al., 2005). In general, biomarkers can be analyzed by different 
methods. The two most commonly used ones are fluorescence in situ hybridization 
(FISH) and immunohistochemistry (IHC) (Kaliyappan et al., 2012; Moter & Göbel, 
2000). 
To decide whether therapy before or after surgery would be beneficial, it is helpful to 
use genomic tests to analyze the activity of certain genes in tumors. Growth and 
spread are tumor characteristics that are influenced by certain genes. With the help 
of molecular tests like MammaPrint or OncotypeDX, which are commercially 
available, doctors can predict to a certain degree which pre- or post-operative 
treatments are necessary (Soliman et al., 2020). Without prognostic markers, a lot of 
patient would undergo treatments like chemotherapy without any positive impact on 
the disease while wasting valuable lifetime of a patient. Hence, good prognostic and 
predictive markers also have the potential to strongly improve patient welfare.  
 
 
4.5. Aim of the thesis  
Given the pivotal impact of CAS on tumor biology, there is ample interest in better 
understanding the changes that occur in CAS in patient samples. While knowledge 
regarding transcriptional reprogramming of CAS in both human and canine mCA is 
starting to emerge, it remains entirely unclear to what extent the observed 
transcriptional changes translate to the protein level. To the best of our knowledge, 
there is only one report describing proteomic changes during stromal reprogramming 
in fresh-frozen samples of human mCA (Gandellini et al., 2012; Hanahan & 
Coussens, 2012; Song et al., 2019), and none for canine mCA. This striking shortage 
of data on a highly relevant aspect of tumor biology warrants further investigation.  
FFPE tissue represents a huge resource of patient material that is routinely prepared 
in pathology departments and can be easily stored for decades. However, FFPE 
negatively impacts on the quality and quantity of macromolecules that can be 
isolated from these tissues, making analysis of RNA or protein from such tissue 
challenging. Having already established RNA analysis of microdissected areas from 
such tissue, we set out to define proteomic changes during stromal reprogramming in 
archival FFPE patient samples and to compare them with transcriptomic changes in 
the same tissue. To this end, we isolated CAS and matched normal stroma using 
LCM from a cohort of 14 archival FFPE canine mCAs that we had previously 
characterized using LCM-RNAseq (Hedegaard et al., 2014; Sinicropi et al., 2012; 
Tanca et al., 2012) and analyzed them by LC-MS/MS. By doing so, we aimed to 
address the following key question: i) what are the proteomic changes in CAS from 
canine mCA, ii) how do the changes on the protein level relate to transcriptional 
changes observed in these tissues, and iii) can any of the observed changes be used 
as a prognostic marker for mCA?  
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Answering of these key questions is expected to significantly improve our knowledge 
regarding the biology of canine and human CAS and has the potential to unveil novel 
therapeutic strategies to benefit both canine and human breast cancer patients. 
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Cancer remains one of the most feared diseases as the number of new cases has 
risen over the past decades to 19.3 million with 10 million deaths in 2020 (Sung et 
al., 2021). This makes cancer the number two cause of death worldwide. Among 
women, breast cancer is the most frequently occurring cancer. Despite all the effort 
that is put into cancer research, there is much we do not understand about cancer, 
which translates to our inability to cure all cancer patients. While much research has 
focused on cancer cells, more recent progress has unveiled the pivotal impact of the 
CAS on tumor growth and progression. It has become clear that cancer cells can 
reprogram their surrounding stroma and transform it into CAS, which in turn displays 
tumor-supportive features. Hence, better understanding CAS and its interaction with 
tumor cells has the potential to unveil novel approaches to improve cancer therapy.  
Cancer research strongly relies on model organisms. In this respect, comparative 
analysis of cancer in dogs has tremendous potential to improve our knowledge of the 
human condition. Particularly canine simple mCA are increasingly viewed as a good 
model to understand human breast cancer in a comparative setting.  
Given the prominent role of CAS in the biology of human breast cancer, it is very 
likely to be a central actor in canine mCA, too. While CAS reprogramming in canine 
and human mCA has been analyzed on the transcriptional level, it remains unclear to 
what extent transcriptomic changes therein translate to the protein level, and what 
the proteomic landscape of stromal reprogramming looks like in cancer patient 
samples. Indeed, in many aspects, proteins are the real ‘work-horses’ of a cell and 
strongly determine the function of cells, tissues and entire organs. Protein production 
is influenced by many post-transcriptional mechanisms, which is why mRNA levels 
do not necessarily correlate with protein abundance (Coppin et al., 2018; Hershey et 
al., 2012). Therefore, to better understand CAS reprogramming in both canine and 
human mCA, it is important to know what changes occur in CAS on the protein level. 
To address this question, we set out to characterize the proteomic changes between 
normal stroma and CAS in canine mCAs. Our main focus was to gain insight into the 
following aspects: i) what are the proteomic changes in CAS from canine mCA, 
ii) how do the changes on the protein level correlate with transcriptional changes in 
these tissues, and iii) can any of the observed changes be used as a prognostic 
marker for human mCA?  
 
 
6.1. Proteomic analysis of CAS and normal stroma from LCM-FFPE patient 
tissue  
To address these questions, we harnessed the validity of spontaneous canine simple 
mCA as a relevant model of human mCA, that extends also to CAS reprogramming, 
to gain insight into the proteomic landscape of stromal reprogramming in both human 
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and canine breast cancer. By investigating proteomic changes in microdissected 
FFPE patient tissues using LC-MS/MS, we obtained the first dataset to assess 
proteomic changes between CAS and normal stroma of canine mCA. Our results 
demonstrate the feasibility to identify proteins from microdissected FFPE patient 
samples and reveal marked changes in protein composition between CAS and 
normal stroma in canine mCA. These results contribute to a better understanding of 
the involvement of stromal genes in development and progression of both canine and 
human mCA, serve as a basis for further in-depth mechanistic studies of involved 
genes, and have the potential to reveal both novel prognostic markers and 
therapeutic targets.  
 
Archival FFPE patient samples represent a huge resource of patient material that is 
routinely prepared in pathology departments and can be easily stored for decades. 
However, FFPE negatively impacts on the quality and quantity of macromolecules 
that can be isolated from these tissues, making analysis of RNA or protein from such 
tissue challenging. Despite these difficulties, recent years have brought a big 
improvement in extraction and analysis methods, rendering the analysis of RNA or 
proteins from FFPE tissue possible while also demonstrating a good consistency 
between results from FFPE and fresh-frozen tissue (Heaton & Master, 2011; Smith et 
al., 2013). Bulk analysis of fresh-frozen human breast cancer has revealed significant 
differences between malignant and matched non-tumor tissue (Drev et al., 2017; 
Puré & Blomberg, 2018). The positive aspects in terms of quality of extracted 
macromolecules when using fresh-frozen tissue are heavily counterbalanced by the 
disadvantages that arise through the need of a high grade of coordination to achieve 
proper collection and storage. Furthermore, tissue morphology of fresh-frozen tissue 
is inferior to that of FFPE. And finally, using fresh-frozen tissue precludes the use of 
most archival samples, which are generally processed as FFPE. Indeed, proteomic 
analysis has also been shown to work for microdissected FFPE tissue (reviewed in 
Nissen et al., 2019). Hence, this possibility to analyze specific areas of archival 
patient samples by both RNAseq and proteomics unlocks a novel dimension of hard-
to-analyze samples for investigation.  
 
6.2. The proteomic landscape of CAS and normal stroma in canine mCA 
Our proteomic approach revealed several interesting insights into CAS-
reprogramming. Importantly, the most significantly deregulated proteins are all 
produced by stromal cells, thus validating our approach to isolate and analyze 
stroma. Some of the proteins, such as Collagen type VIII, Fibrillin, LTBP2, are known 
to be of mainly stromal origin and are upregulated in colorectal cancer (Drev et al., 
2017; Puré & Blomberg, 2018) Especially the composition of collagens seemed to 
shift quite strongly between normal stroma and CAS. The most significantly 
upregulated collagens that we found in CAS were the following: COL4A1, COL6A3, 
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COL8A2, COL11A1, COL11A2, COL12A1, and COL15A1. Most of the collagens are 
produced by stromal cells, and fibrillar collagens and collagen VI for instance are 
collagens known to be produced by CAFs (reviewed in Nissen et al., 2019). 
Collagens have been found to have important roles in different types of cancer, for 
example collagen XII in gastric cancer and ovarian cancer (Duan et al., 2018; 
Januchowski et al., 2016; Jiang et al., 2019) where it has been associated with drug 
resistance and poor overall survival, or collagen XI which is also expressed in CAFs 
(Freire et al., 2014). Overexpression of collagen XI can be found in different types of 
cancer, for example breast cancer (Freire et al., 2014; Halsted et al., 2008), non-
small cell lung cancer (Shen et al., 2016), colorectal cancer (Fischer, 2001) and 
ovarian cancer (Y.-H. Wu et al., 2014). Its association with invasiveness and 
malignancy (Freire et al., 2014), poor clinical outcome and capabilities to promote 
metastasis reflects the importance of collagen type XI in cancer progression (Freire 
et al., 2014; Jia et al., 2016; Shen et al., 2016). Additionally, genes of collagen XI and 
XII are also among the most upregulated genes in CAS from human breast cancer 
(Ma et al., 2009). Hence, the upregulation of these collagens on the protein level is in 
strong accordance with the findings of other studies and further highlights them as 
interesting targets for further mechanistic investigation. 
 
Gene ontology analysis revealed a strong involvement of the production and 
regulation of the TNF superfamily, with the regulating molecules THBS1, LTF, ACP5, 
and BPI that were all strongly upregulated in CAS compared to normal stroma. TNF 
is known to be frequently upregulated in human epithelial malignancies such as 
breast cancer (Boldrini et al., 2000; Katerinaki et al., 2003; Miles et al., 1994). Both 
tumor cells and tumor-associated macrophages are able to produce TNF. On the 
cellular level, TNF exerts its effects through its receptors that activate distinct 
signaling pathways. On one hand, TNF is involved in all stages of human breast 
cancer development, affecting tumor cell proliferation and survival, epithelial-to-
mesenchymal-transformation, metastasis and recurrence (reviewed in Cruceriu et al., 
2019). On the other hand, TNF also possesses some anticancer properties through 
inducing cancer cell death (reviewed in Wang & Lin, 2008). THBS1 
(Thrombospondin-1) is a protein that acts in the tumor microenvironment to inhibit 
angiogenesis, regulate antitumor immunity, stimulate tumor cell migration, and 
regulate the activities of extracellular proteases and growth factors (Roberts, 2005; 
Stenina-Adognravi et al., 2018). LTF (Lactotransferrin) is an iron-binding glycoprotein 
which is stored in specific granules in neutrophils. High amounts of LTF can be found 
especially in milk and fluids of the digestive tract. It regulates the immune response 
and protects against infection and septic shock as an antibacterial and anti-
inflammatory agent (Conneely, 2001; Ward et al., 2005). Because of its anti-
inflammatory function, LTF can inhibit the secretion of TNF (Choe & Lee, 2000; 
Legrand et al., 2005; Machnicki et al., 1993). Nevertheless, it’s function in breast 
cancer is still unclear. ACP5 (Tartrade-resistant acid phosphatase 5), which is 
essential for bone resorption and osteoclast differentiation, promotes cell motility 
through the modulation of focal adhesion kinase phosphorylation. Its expression is 
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found in cells of the mononuclear phagocyte system, in a variety of differentiated 
cells of the myeloid lineage such as granulocytes (eosinophils), and in osteoclasts 
(Lamp & Drexler, 2000). Moreover, Gao et al. found ACP5 to be upregulated in lung 
adenocarcinoma tissues and that high expression of ACP correlated with poor overall 
survival (Gao et al., 2018). Bactericidal permeability increasing protein (BPI) is an 
antibacterial and endotoxin-neutralizing protein expressed by epithelial cells. It 
inhibits the release of TNF, especially when it is LPS-induced (Aloisi et al., 2000). 
Further analysis of the involvement of the TNF pathway in CAS of canine and human 
mCA will likely yield interesting data. 
 
The strong role of TGF-beta related signaling that emerged from pathway analysis is 
well supported by literature. TGF-beta naturally possesses both tumor-suppressive 
as well as tumor-promoting qualities, depending on the context. As tumor-promoter 
TGF-beta can support the promotion of tumor growth and invasion, evasion of 
immune surveillance, and metastasis (reviewed in Korpal & Kang, 2010; and 
Massagué, 2008). Also associated with the TGF-beta pathway is PAI-1 (plasminogen 
activator inhibitor-1), a serine protease inhibitor that we found to be strongly 
upregulated in CAS. PAI-1 inhibits tissue plasminogen activator and urokinase, the 
activators of plasminogen and hence fibrinolysis. It promotes invasion and metastasis 
of cancer cells and correlates with poor prognosis in breast cancer (M. Duffy, 2004; 
M. J. Duffy et al., 2014; Wei et al., 2019). Similarly, ITGB1 (integrin beta-1), a 
membrane receptor for e.g. collagen, fibronectin, fibrinogen and others, is strongly 
upregulated in CAS. ITGB1 is involved in cell adhesion and recognition in different 
kind of processes such as tissue repair, metastatic diffusion of tumor cells, immune 
response, embryogenesis, and hemostasis. It is known to correlate with low survival 
rates of triple negative breast cancer. Finally, as it can regulate the store-operated 
calcium influx, ITGB1 also regulates cancer cell migration (Klahan et al., 2016; Sun 
et al., 2018). 
In essence, the results of our proteomic analysis of subsections of FFPE tissue yields 
detailed insight into the proteomic landscape of changes occurring during stromal 
reprogramming in mCA. 
  
 
6.3. Substantial correlation between proteomic and transcriptomic changes 
during stromal reprogramming  
Comparative studies have found that correlations between mRNA and protein levels 
in model organisms can be relatively weak and uncertain or moderately positive 
(Vogel & Marcotte, 2012). With respect to the entire data set, the correlation 
coefficient between transcriptomics and proteomics was R=0.3626, similar to what 
has been reported for other tissues before (Ghazalpour et al., 2011; Greenbaum et 
al., 2003; Maier et al., 2009; Popovic et al., 2018). But setting the threshold of the 
adjusted p-value at 0.05 increased the correlation coefficient to 0.5451. Similarly, 
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restricting the analysis to the top 20 targets from either the transcriptomic or 
proteomic dataset further increased the correlation, suggesting that the more targets 
are deregulated, the more consistent the correspondence between mRNA and 
protein levels become. This was further supported by the fact that analysis of 
pathway enrichment in both datasets revealed a comparable picture between 
transcriptomics and proteomics.  
 
In summary, while the proteomics-based analysis of LCM-FFPE tissue yielded fewer 
targets than the transcriptomic approach, the protein and transcript levels showed 
substantial correlation, especially for the most deregulated targets and pathways. 
 
 
6.4. Prognostic potential of stromal changes in canine mCA 
By leveraging the relevance of canine CAS as a model of the human disease, we 
establish increased expression of LTBP2, IGFBP2, COL6A5, POSTN, FN1, COL4A1, 
COL12A1, PLOD2, COL4A2, and IGFBP7 to be strongly correlated with worse 
overall survival for human breast cancer patients. Validation of increased Collagen IV 
and Fibronectin on protein level in canine CAS further substantiates these findings. 
Of note, PDGFRB and FAP, two CAS markers that we have previously validated as 
upregulated using IHC (Ettlin et al., 2017) were also found to be upregulated using 
proteomics.  
LTBP2 is critically involved in regulation of TGF-beta signaling (Robertson et al., 
2015) and its expression is significantly elevated in human breast cancer in 
correlation with clinical stage and other adverse prognostic factors (Gu et al., 2018). 
As a regulator of PI3K signaling, the expression IGFBP2 is strongly correlated with 
grade of malignancy in many tumors and especially in breast cancer (Hoeflich & 
Russo, 2015). Collagen VI has been recently identified as driver of invasion and 
metastasis of breast cancer and high protein levels of Collagen VI have been found 
by bulk tumor proteomic analysis of more than 500 human cancers  (Cescon et al., 
2015; F. Chen et al., 2019; Wishart et al., 2020). Strongly elevated levels of both 
POSTN and FN1 are well documented in a wide variety of tumors, including breast 
cancer, and have been shown to promote tumor invasion and metastasis through 
manifold effects on different cancer hallmarks (reviewed in (Efthymiou et al., 2020; 
González-González & Alonso, 2018)). Similarly, Collagen IV is positively correlated 
with larger and more aggressive breast tumors (Ioachim et al., 2002) and has been 
shown to promote cancer cell invasion and migration (Xu et al., 2019). Burnier et al. 
revealed that increased levels of type IV collagen correlate with an increase in liver-
metastasis of primary tumors such as colorectal cancer (Burnier et al., 2011). High 
PLOD2 expression is associated with increased mortality risk in breast cancer 
(Gilkes et al., 2013). Functionally, it promotes fibrillar collagen formation and thereby 
increases tumor stiffness and is required for metastasis. IGFBP7 expression in tumor 
cells has been suggested to be anti-neoplastic (Jin et al., 2020). However, when 
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expressed in CAS, it has growth-promoting effects on tumor cells through a paracrine 
signaling mechanism that can promote anchorage-independent growth of tumor cells 
(Rupp et al., 2015). Interestingly, IGFBP7 also binds to Collagen IV(Jin et al., 2020). 
The fact that on the transcriptomics level only one of the top 10 adverse genes 
(Amini et al., 2020) actually correlate with worse overall survival, while on the protein 
level there are 4 among these top 10 targets that predict worse overall survival 
suggests that proteomic changes could potentially be a better predictor than 
transcriptomic changes, at least when it comes to analyzing expression of stromal 
genes in bulk tissue. This might be due to the fact that RNAseq data usually turns 
back many more differentially expressed targets than proteomics analysis (in this 
study we detected 13% of all transcripts on the proteomic level). Important 
transcriptomic changes in single targets are therefore more likely to be 
‘overshadowed’ by other targets that might not have anything to do with overall 
survival in contrast to the relatively ‘smaller’ proteomic dataset. Another possibility is, 
that proteomic detection could be biased towards the most abundant proteins, which 
might also hold more biological relevance. While it’s currently not possible to 
unequivocally answer this question, this clearly further underlines the point that 
transcriptomic and proteomic changes are not always in direct concordance and that 
proteomic profiling of distinct tissue compartments can provide novel insight into 
biological questions that go beyond validation of RNAseq data.  
 
Hence, by providing validation of the deregulation of these previously identified 
differentially expressed transcripts on protein level, our proteomic analysis of CAS 
reprogramming further strengthens the role of these targets as disease-modulating 




In conclusion, the data presented in this thesis demonstrate the feasibility to identify 
proteins from microdissected FFPE sections of patient samples. With regards to the 
main aims of this thesis, by revealing the detailed proteomic landscape of stromal 
reprogramming, I was able to shed light on the proteomic changes that occur in CAS 
from canine mCA, thereby addressing Aim 1. Furthermore, addressing Aim 2, 
comparative analyzes between proteomic and transcriptomic data from the same 
patient samples revealed the extent of correlation between proteomic and 
transcriptomic changes in these tissues. Finally, with regards to Aim 3 of this thesis, 
by translating our findings to datasets of human tissues, we were able to identify 
several deregulated proteins with prognostic value for human patients. Taken 
together, these results have the potential to contribute to a better understanding of 
the involvement of stromal genes in development and progression of canine and 
human breast cancer. 
22 
 
6.6. Outlook and potential future research directions  
In the future, the results presented in this thesis will serve as a starting point for 
mechanistic follow-up studies to further understand the role of the stromal genes that 
are strongly deregulated between normal stroma and CAS in development and 
progression of both canine and human mCA.  
 
To do so, one can envisage the use of a multitude of possible approaches ranging 
from in vitro cell culture studies to in vivo experiments involving e.g. rodent models of 
tumor development. With respect to in vitro cell culture systems, mechanistic 
interrogation using indirect or direct coculture models of stromal cells and cancer 
cells can be used to dissect the effect of the targets in question on tumor cell growth, 
motility and invasiveness. In such settings, loss- and gain-of-function approaches 
using siRNA, shRNA and/or CRISPR-Cas9 in stromal cells can be used to address 
the effect of depletion or overexpression of the target on cancer cells. Indirect 
cocultures would require transfer of conditioned medium from one cell type to the 
other to observe cancer cell behavior, while in direct coculture systems, both cell 
types would be grown together in direct contact. Direct coculture systems include 
spheroids, organoids, and organotypic tissue models and are likely to be better 
models of the real in vivo situation than 2D-culture based assays (Jenei et al., 2011; 
Kim et al., 2020; Yakavets et al., 2020). One of the latest techniques to gain 
mechanistic insight into different processes in the microenvironment regarding cell-
cell and cell-stromal interactions, is 3D bioprinting. In 3D bioprinting, so called bioinks 
are layered by computers to generate a viable 3D construct. The materials of bioinks 
differ from scaffold-based and scaffold-free bioinks. Scaffold-based bioinks, the most 
typical type, consist of cells, hydrogels such as agarose or collagen type I, 
decellularized matrix components, and microcarriers which allow cells to attach and 
grow and therefore expand (Hospodiuk et al., 2017; Khoshnood & Zamanian, 2020; 
Y. Yu et al., 2016). 3D bioprinting is already used to study the biology and drug 
response in breast cancer, using human cancer cells (Bahcecioglu et al., 2020; 
Belgodere et al., 2018; Reid et al., 2019; Y. Wang et al., 2018). In contrast, in 2D 
culture methods, cells grow on rigid materials like glass or polystyrene without a 
physiological microenvironment, those stromal proteins cannot be observed to the 
same scale.  
As the microenvironment is viewed as an interesting target for therapy (Hirata & 
Sahai, 2017; T. Wu & Dai, 2017), more detailed insight into the interplay between 
tumor cells and the surrounding stroma is highly needed. If validated mechanistically, 
the novel targets identified in this thesis have the potential to inspire future 
therapeutic approaches to help human and veterinary patients with cancer in general, 
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